Charmacy Pharmaceutical Co., Ltd. provided earnings guidance for the ended 31 December 2021. For the period, the group is expected to report a net profit attributable to the shareholders of the parent company of approximately RMB 21.00 million to RMB 25.00 million for the Year, representing a decrease of approximately 38% to 48% as compared with that of the year ended 31 December 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.61 HKD | +0.12% | -8.01% | -33.56% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.56% | 119M | |
-38.84% | 13.75B | |
-36.57% | 10.33B | |
-10.38% | 7.94B | |
+4.30% | 5.86B | |
-14.62% | 5.69B | |
-3.21% | 4.65B | |
+69.95% | 4.46B | |
-8.55% | 3.79B | |
-22.93% | 3.05B |
- Stock Market
- Equities
- 2289 Stock
- News Charmacy Pharmaceutical Co., Ltd.
- Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021